Richard James (Yaacov) Lawrence, M.A., M.B.B.S., M.R.C.P.(UK)

Contact Dr. Lawrence

111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107

(215) 955-6702
(215) 955-0412 fax

Medical School
Jesus College, Cambridge, UK

University College of London Hospital, London, England

Residency
Radiation Oncology, Sheba Medical Center, Tel Aviv, Israel

Fellowship
Radiation Oncology, Thomas Jefferson University , Philadelphia, PA

Board Certification
2009: Board Eligible

University Appointment
2009: Assistant Professor

Awards
2009 Young Investigator Award, American Society of Clinical Oncology 2009 Merit Award for outstanding abstract, American Society of Clinical Oncology

Research and Clinical Interests
Drug development in Radiation oncology, primary and secondary brain tumors, radiation toxicity to the brain

Publications

Most recent Peer-reviewed Publications

1. The addition of amifostine to carboplatin and paclitaxel based chemoradiation in locally advanced non-small cell lung cancer: Long-term follow-up of Radiation Therapy Oncology Group (RTOG) randomized trial 9801
2. Predictors of radiation oncology resident research productivity
3. Association between metabolic syndrome, diabetes mellitus and prostate cancer risk
4. A phase i study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas
5. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers
6. Lymph node ratio predicts the benefit of post-operative radiotherapy in oral cavity cancer
7. Reply to a difficult detection can influence survival analysis
8. Radiotherapy improves survival in unresected stage I-III bronchoalveolar carcinoma
9. Quality assurance peer review chart rounds in 2011: A survey of academic institutions in the United States
10. Conditional survival probabilities for patients with resected pancreatic adenocarcinoma
11. Improving prognosis of glioblastoma in the 21st century: Who has benefited most?
12. Implanted dosimeters identify radiation overdoses during IMRT for prostate cancer
13. Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data
14. Characterization and outcomes of optic nerve gliomas: A population-based analysis
15. mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer
16. Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts
17. Delayed initiation of radiotherapy for glioblastoma: How important is it to push to the front (or the back) of the line?
18. Patient-oriented cancer information on the internet: A comparison of wikipedia and a professionally maintained database
19. Early toxicity predicts long-term survival in high-grade glioma
20. From survival to survivorship: Late side effects become an issue in high-grade glioma

View All Publications